High performance liquid chromatography analysis of 9-(2′,3′-dideoxy-2′β-fluoro-D-threo-penta furanosyl) adenine and its metabolite in human plasma using solid-phase extraction on a polyfluorinated reversed stationary phase

✍ Scribed by Hassan Y. Aboul-Enein; Suhair Abu-Zaid

• Publisher: John Wiley and Sons
• Year: 2001
• Tongue: English
• Weight: 90 KB
• Volume: 15
• Category: Article
• ISSN: 0269-3879
• DOI: 10.1002/bmc.70

✦ Synopsis

Abstract

A quick and sensitive reversed‐phase HPLC method has been developed for the analysis of 2′‐β ‐fluoro‐2′,3′‐dideoxy adenosine (F‐ddA), the acid‐stable anti‐AIDS drug, and its metabolite 2′‐fluoro‐2′,3′‐dideoxy inosine (F‐ddI) in human plasma using polyfluorinated stationary phase column (Fluo fix, 15 cm, 4.0 mm i.d., 5 µm particle size). The mobile phase consisted of ammonium phosphate buffer solution (10 mM) adjusted with phosphoric acid 85% to pH 6.8:dimethyl formamide (97:3, v/v). F‐ddA and F‐ddI were monitored by UV–visible detector at 258 and 247 nm, respectively. The recoveries of F‐ddA and F‐ddI from plasma using a C~18~ solid‐phase extraction cartridge were 99.2% and 99.7%, respectively. Copyright © 2001 John Wiley & Sons, Ltd.

Abbreviations used:

AIDS

acquired immunodeficiency syndrome

AZT

zidovudine

CNS

central nervous system

ddA

2′,3′‐dideoxy adenosine

ddC

2′,3′‐dideoxy cytidine

ddG

2′,3′‐dideoxy Guanosine

ddI

2′,3′‐dideoxy inosine

ddT

2′,3′‐dideoxy thymidine

FDA

food and drug administration

F‐ddA

2′‐fluoro‐2′,3′‐dideoxy adenosine

F‐ddI

2′‐fluoro‐2′,3′‐dideoxy inosine

HIV

human immunodeficiency virus

HPLC

high performance liquid chromatography.